Hilary Blacklock
Overview
Explore the profile of Hilary Blacklock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chai K, Wellard C, Thao L, Aoki N, Moore E, Augustson B, et al.
EJHaem
. 2024 Aug;
5(4):690-697.
PMID: 39157592
Serious infection is common in patients with multiple myeloma due to immune deficiency from the underlying disease and/or its treatment. Immunoglobulin replacement is one approach to reduce infection risk in...
2.
Ho P, Moore E, Wellard C, Quach H, Blacklock H, Harrrison S, et al.
Br J Haematol
. 2024 Jul;
205(4):1337-1345.
PMID: 38965706
A decade after International Myeloma Working Group (IMWG) biomarkers (SLiM criteria) were introduced, this real-world study examined their impact on diagnosis, therapy and outcomes in myeloma. Using the ANZ MRDR,...
3.
McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, et al.
Br J Haematol
. 2022 Jul;
198(5):830-837.
PMID: 35818641
The frequency and causes of early mortality in patients with newly diagnosed multiple myeloma (NDMM) have not been well described in the era of novel agents. We investigated early mortality...
4.
Moore E, Blacklock H, Wellard C, Spearing R, Merriman L, Poplar S, et al.
Clin Lymphoma Myeloma Leuk
. 2022 May;
22(8):e762-e769.
PMID: 35501256
Background: Māori and Pacific peoples (MPP) in New Zealand (NZ) have poorer health outcomes than other ethnicities. However, this has not been clinically investigated in multiple myeloma (MM). Using data...
5.
Boyle S, Wellard C, Moore E, Blacklock H, Harrison S, Ho P, et al.
Eur J Haematol
. 2021 Jun;
107(4):497-499.
PMID: 34129711
No abstract available.
6.
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison S, et al.
Bone Marrow Transplant
. 2021 May;
56(10):2533-2543.
PMID: 34011965
Supported by clinical trial proven survival benefit, clinical guidelines recommend upfront autologous stem cell transplantation (ASCT) for eligible MM patients. However, reported real-world utilisation is lower than expected (40-60%). We...
7.
Bergin K, Wellard C, Moore E, McQuilten Z, Blacklock H, Harrison S, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Mar;
21(6):e510-e520.
PMID: 33785297
Background: Real-world multiple myeloma (MM) data are scarce, with most data originating from clinical trials. The Myeloma and Related Diseases Registry (MRDR) is a prospective clinical-quality registry of newly diagnosed...
8.
Ameratunga R, Ahn Y, Tse D, Woon S, Pereira J, McCarthy S, et al.
Allergy Asthma Clin Immunol
. 2019 Dec;
15:78.
PMID: 31827542
Background: Common variable immunodeficiency disorders (CVID) are a rare group of primary immune defects, where the underlying cause is unknown. Approximately 10-20% of patients with typical CVID have a granulomatous...
9.
Mateos M, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, et al.
Lancet Haematol
. 2019 Jul;
6(9):e459-e469.
PMID: 31327687
Background: Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and...
10.
Ho P, Moore E, McQuilten Z, Wellard C, Bergin K, Augustson B, et al.
Clin Lymphoma Myeloma Leuk
. 2019 Jun;
19(8):e415-e424.
PMID: 31208889
Background: Renal impairment (RI) is a common complication of multiple myeloma (MM) and remains a poor prognostic factor despite improved survival with newer therapies. Patients And Methods: We evaluated baseline...